Recent Company News

• 10:05 AM ET Aug 03, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (162 total)

• 11:16 PM ET Jul 30, 2026
  

  Bicycle Therapeutics assumed outperform at Oppenheimer; prior rating was outperform ($4.01, 0.00)

• 10:35 AM ET Jul 30, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (124 total)

• 07:07 AM ET Jul 30, 2026
  

  Bicycle Therapeutics reports Q2 EPS ($0.72) vs FactSet ($0.58) [9 est, ($0.75)-(0.37)] ($3.86, 0.00)

• 10:01 AM ET Jun 25, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (324 total)

• 10:03 AM ET Jun 11, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (204 total)

• 10:05 AM ET Jun 05, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (106 total)

• 02:11 PM ET May 29, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 31-May

• 02:22 PM ET May 22, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 24-May

• 05:15 PM ET May 21, 2026
  

  Bicycle Therapeutics to present initial Duravelo-2 data at 2026 ASCO annual meeting ($4.45, 0.00)